- Current report filing (8-K)
December 23 2009 - 5:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
December 22, 2009
AVI BioPharma, Inc.
(Exact name of registrant as specified in its charter)
Oregon
|
|
001-14895
|
|
93-0797222
|
(State or other
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
|
jurisdiction of
|
|
|
|
Identification
No.)
|
incorporation)
|
|
|
|
|
3450 Monte Villa Parkway, Suite 101
Bothell, WA 98021
(Address of principal executive offices)
(425) 354-5038
Registrants telephone number, including area code
(Former name or former address,
if changed since last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item
7.01. Regulation FD Disclosure.
On December 22,
2009, AVI BioPharma, Inc. (the Company) issued a press release
announcing initial efficacy data from the ongoing Phase 1b/2 clinical trial of
AVI-4658 for the systemic treatment of patients with Duchenne muscular
dystrophy (DMD), a genetic muscle wasting disease caused by failure to produce
dystrophin. A copy of this press
release is attached hereto as Exhibit 99.1.
The information in this
Item 7.01 and the press release attached as Exhibit 99.1 to this Form 8-K,
shall not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, nor shall this Item 7.01, such Exhibit 99.1, or
any of the information contained therein be deemed incorporated by reference in
any filing under the Securities Exchange Act of 1934 or the Securities Act of
1933, except as shall be expressly set forth by specific reference in such
filing.
Item
9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Press release, dated
December 22, 2009, entitled Systemic Treatment With AVI-4658
Demonstrates RNA Exon Skipping and Dystrophin Protein Expression in Duchenne
Muscular Dystrophy Patients
|
2
SIGNATURES
Pursuant to the requirements
of Section 13 or 15(d) of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of Bothell, State of
Washington, on December 23, 2009.
|
AVI
BioPharma, Inc.
|
|
|
|
By:
|
/s/ Leslie Hudson,
Ph.D.
|
|
|
|
|
|
Leslie Hudson, Ph.D.
|
|
|
President
and Chief Executive Officer
(Principal Operating Officer)
|
3
EXHIBIT INDEX
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Press release, dated
December 22, 2009, entitled Systemic Treatment With AVI-4658
Demonstrates RNA Exon Skipping and Dystrophin Protein Expression in Duchenne
Muscular Dystrophy Patients
|
4
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024